LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...
NEW YORK, Jan 25 (Reuters) - Amgen Inc. on Thursday disclosed negative findings in studies of its Aranesp anemia drug and Vectibix colon cancer treatment, including a higher risk of death among cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback